4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Prostate Cancer|Metastasis
Interventions: DRUG: Pamidronate|DRUG: Denosumab|DRUG: Zoledronate
Sponsor: Ottawa Hospital Research Institute